Ultime notizie per Owens & Minor (NYSE:OMI) Azioni

Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Owens & Minor Inc

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Omid Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OmiseGO - United States Dollar

<a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024" title="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024">https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024</a>

News

FDA Issues Warning Letter To Owens & Minor Over Serious Quality Control And Compliance Failures In Sterile Medical Device Manufacturing, Requires Corrective Actions Within 15 Days

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $17.9, along with a high estimate of $25.00 and a low estimate of $14.00. This current average represents a 17.13% decrease from the previous average price target of $21.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1730836906_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Owens &amp; Minor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Owens &amp; Minor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Owens &amp; Minor compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Owens &amp; Minor's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Owens &amp; Minor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OMI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Owens &amp; Minor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Owens &amp; Minor's Background</h2>
Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products &amp; Healthcare Services and Patient Direct. The Products &amp; Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products &amp; Healthcare Services segment.
<h3>Financial Milestones: Owens &amp; Minor's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Owens &amp; Minor showcased positive performance, achieving a revenue growth rate of 4.2% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Owens &amp; Minor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.64%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Owens &amp; Minor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.61%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.77, Owens &amp; Minor faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Owens & Minor

UBS analyst Kevin Caliendo maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $28 to $25.

Price Target

UBS Maintains Buy on Owens & Minor, Lowers Price Target to $25

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $21 to $18.5.

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $18.5

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $24 to $28. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Hims &amp; Hers Health shares closed at $20.76 on Monday. See how other analysts view this stock.</li>
<li>Benchmark raised the price target for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from $440 to $450. Benchmark analyst Matthew Harrigan maintained a Buy rating. Charter Communications shares closed at $375.83 on Monday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $165 to $115. Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight. Celanese shares closed at $123.50 on Monday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $95 to $75. Telsey Advisory Group analyst Joseph Feldman downgraded the stock from Outperform to Market Perform. Dollar Tree shares settled at $66.81 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna slashed Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) price target from $65 to $55. Susquehanna analyst Christopher Rolland maintained a Positive rating. Lattice Semiconductor shares closed at $51.89 on Monday. <a href="https://www.benzinga.com/quote/LSCC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) price target from $7 to $5. Baird analyst Tristan Gerra maintained an Outperform rating. Navitas Semiconductor shares closed at $2.61 on Monday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital increased the price target for Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from $22 to $22.5. Loop Capital analyst Rick Paterson downgraded the stock from Buy to Hold. Air Transport shares settled at $22.00 on Monday. <a href="https://www.benzinga.com/quote/ATSG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) price target from $19 to $14. Baird analyst Eric Coldwell maintained a Neutral rating. Owens &amp; Minor shares closed at $12.00 on Monday. <a href="https://www.benzinga.com/quote/OMI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted the price target for Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from $25 to $36. Stifel analyst Paul Matteis upgraded the stock from Hold to Buy. Alkermes shares closed at $26.59 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted MasTec, Inc.. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) price target from $133 to $173. Truist Securities analyst Jamie Cook upgraded the stock from Hold to Buy. MasTec shares closed at $132.61 on Monday. <a href="https://www.benzinga.com/quote/MTZ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ALKS

ATSG

CHTR

DLTR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LSCC

NVTS

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $19 to $14.

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $14

WIIM

Owens & Minor shares are trading higher after the company reported better-than-expected Q3 financial results and raised the lower end of its FY24 guidance.

On Monday,&nbsp;Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported the third quarter of 2024 adjusted EPS of $0.42, down from $0.44 reported a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.41</a>.
The company reported sales of $2.72 billion, up 5% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41708956/owens-minor-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $2.68 billion</a>.
Patient Direct revenue of $687 million, up 6% year-over-year, driven by strength in several categories led by diabetes and sleep supplies.
Products &amp; Healthcare Services revenue of $2.0 billion, up 5%, driven primarily by strong same-store sales in the Medical Distribution division and one additional sales day.
Third quarter 2024 operating income of $24 million and adjusted operating income of $84 million. Adjusted EBITDA increased 5% to $142 million.
"Our third quarter results demonstrated our ability to deliver on our commitments both near-term as well as on our strategic initiatives. Our Patient Direct segment continues to perform well in the growing home-based care space while we continue investing to support long-term profitable growth. In our Products &amp; Healthcare Services segment, we continue to see solid top-line results, especially within our Medical Distribution division supported by recent wins and deepened relationships with our existing customers," said Edward A. Pesicka, President &amp; Chief Executive Officer of Owens &amp; Minor.
Guidance:&nbsp;Owens &amp; Minor see full-year 2024 revenue of $10.6 billion-$10.8 billion compared to the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40130112/healthcare-logistics-provider-owens-minor-calls-q2-performance-consistent-with-expectations-reitera" rel="noreferrer noopener">prior guidance of</a> $10.5 billion-$10.9 billion and consensus of $10.713 billion.
The healthcare logistics&nbsp;company expects 2024 adjusted EPS of $1.45-$1.55, compared to prior guidance of $1.40-$1.70 and the consensus of $1.60.
Pesicka concluded, "Looking ahead, we are confident in our ability to show good sequential growth and cash flow from the third to fourth quarter, which positions us well as we enter 2025. Each of the segments should benefit from seasonality and investments of the last several quarters as we finish 2024 and look to the future."
Price Action:&nbsp;OMI stock is down 8.27% at $12.26 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41710271/roaring-kitty-stock-chewy-set-to-join-s-p-midcap-400-index-will-replace-stericycle" target="_blank" rel="noreferrer noopener">Roaring Kitty Stock Chewy Set to Join S&amp;P MidCap 400 Index, Will Replace Stericycle</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

Health Solutions Provider Owens & Minor's Q3 Earnings: Revenue And EPS Beat, Trims Annual Outlook

Owens & Minor Expects 2024 Adjusted EPS Of $1.45-$1.55  Compared To Prior Guidance Of $1.40-$1.70, Versus Consensus Of $1.60

2024 Financial Outlook
The Company's recently revised financial guidance; summarized below:
<ul>
<li>Revenue for 2024 to be in a range of $10.6 billion to $10.8 billion</li>
<li>Adjusted EBITDA for 2024 to be in a range of $540 million to $550 million</li>
<li>Adjusted EPS for 2024 to be in a range of $1.45 to $1.55</li>
</ul>
The Company's outlook for 2024 contains assumptions, including current expectations regarding the impact of general economic conditions, including inflation, and the continuation of pressure on pricing and demand in our Products &amp; Healthcare Services segment. Key assumptions supporting the Company's 2024 financial guidance include:
<ul>
<li>Gross margin rate of 20.5% to 21.0%</li>
<li>Interest expense of $142 to $144 million</li>
<li>Adjusted effective tax rate of 27.5% to 28.5%</li>
<li>Diluted weighted average shares of ~78.5 million</li>
<li>Capital expenditures of $225 to $235 million</li>
<li>Stable commodity prices</li>
<li>FX rates as of 12/31/2023</li>
</ul>

Owens & Minor Expects 2024 Revenue Of $10.6B-$10.8B Compared To Prior Guidance Of $10.5B-$10.9B And Consensus Of $10.713B

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.41 by 2.44 percent. This is a 4.55 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $2.72 billion which beat the analyst consensus estimate of $2.68 billion by 1.50 percent. This is a 4.98 percent increase over sales of $2.59 billion the same period last year.

Owens & Minor Q3 2024 Adj EPS $0.42 Beats $0.41 Estimate, Sales $2.72B Beat $2.68B Estimate

Large Cap

Management

Owens & Minor Has Appointed Jonathan Leon As Executive Vice President And Chief Financial Officer, Effective Immediately

Owens &amp; Minor, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>) has announced a partnership with Google Cloud, owned by the parent holding company, Alphabet&nbsp;to enhance the existing capabilities of its cloud-based clinical inventory management system, QSight. The collaboration will combine the company&#39;s expertise in optimizing the healthcare supply chain with Google Cloud&#39;s Vertex AI platform, to tackle the modern supply chain management complexities and support the patients more effectively.
The latest development demonstrates the progress Owens &amp; Minor has been making toward its strategic goals for the Products &amp; Healthcare Services segment.
Following the news, shares of OMI edged up 0.2% to $14.42 at Tuesday&#39;s close. By staying at the forefront of technology, including making investments with one of the most renowned innovators in the market, the company consistently delivers value to its customers and improves clinician efficiency. We expect the market sentiment on OMI stock to stay positive around this development.
<h2>Significance of OMI&#39;s New Partnership</h2>
The implications of inefficient inventory management in healthcare can extend beyond the stockroom and into the operating room. This includes the risks of expired products being used in patient care and loss of inventory if products expire before. There is also an increasing pressure to deliver high-quality care while managing costs and optimizing efficiency &mdash; with less support from clinical staff.
However, traditional clinical inventory management systems often lack the real-time visibility and predictive capabilities to oversee the complex healthcare supply chains, leading to increasing costs and higher workloads for clinical staff.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/dd/77474.jpg?v=1748561454" />
Image Source: Zacks Investment Research
The partnership between Owens &amp; Minor and Google Cloud aims to focus on enhancing QSight&#39;s ability to help hospitals and health systems optimize how they manage the thousands of medical-grade supplies, high-value surgical implants and human tissue products required for patient care. The company will also lay the foundation for future platform and service innovations with the potential to improve the QSight customer experience.
<h2>Favorable Industry Prospects for Owens &amp; Minor</h2>
A report by Research and Markets&nbsp;valued the healthcare inventory management software market at $331.5 million in 2021 and forecasts it to see a compound annual rate of 8.9% through 2028.
The rising complexity of the healthcare supply chain, such as worldwide sourcing, diversified product portfolios, regulatory constraints, and the demand for real-time monitoring, have increased the need for sophisticated inventory management systems. Healthcare organizations are implementing advanced inventory management solutions that provide greater visibility, automation and analytics.
<h2>Other Major Developments Within OMI</h2>
In July 2024, Owens &amp; Minor announced a definitive agreement to acquire Rotech Healthcare Holdings, Inc., a home medical equipment provider based in the United States, for $1.36 billion in cash. The acquisition directly aligns with the company&#39;s broader strategy to expand into the fast-growing home-based care space. In addition, it also bolsters its Patient Direct product offerings through expansion across a complementary portfolio including Respiratory, Sleep Apnea, Diabetes and Wound Care.
<h2>OMI Stock Price Performance</h2>
In the past year, Owens &amp; Minor shares have plunged 10.8% against the industry&#39;s 18.4% growth.
<h2>OMI Estimate Trend and EPS Surprise History</h2>
In the past 30 days, estimates for Owens &amp; Minor&#39;s 2024 earnings have remained constant at $1.57 per share. The company beat estimates in each of the trailing four quarters, the average surprise being 11.1%.
<h2>OMI&#39;s Zacks Rank and Top MedTech Stocks</h2>
Owens &amp; Minor currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) and AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Boston Scientific&#39;s shares have risen 55.9% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 141.4% in the past year compared with the industry&#39;s growth of 15.7%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
<a href="https://www.zacks.com/stock/news/2335232/owens-minor-stock-to-gain-from-new-collaboration-with-google-cloud?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335232">To read this article on Zacks.com click here.</a>

Earnings Beats

Small Cap

AXGN

Owens & Minor Stock to Gain From New Collaboration With Google Cloud

By partnering with Google Cloud, Owens &amp; Minor will strengthen QSight&#39;s existing inventory management capabilities while laying the foundation for future platform and service innovations with the potential to dramatically improve the QSight customer experience.

GOOG

GOOGL

Owens & Minor Enters New Partnership With Google Cloud; Collaboration Will Enhance Existing QSight Capabilities

JP Morgan analyst Lisa Gill maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Underweight and lowers the price target from $22 to $18.

JP Morgan Maintains Underweight on Owens & Minor, Lowers Price Target to $18

Cardinal Health, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is scheduled to report fourth-quarter fiscal 2024 results on Aug 14, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 6.67%. CAH&#39;s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 12.91%.
<h3>Q4 Estimates</h3>
For the fiscal fourth quarter, the consensus mark for earnings is pegged at $1.72 per share, indicating an improvement of 10.9% from the prior-year quarter&#39;s reported figure. The same for revenues is pinned at $58.72 billion, implying growth of 9.9% year over year.
<h3>Factors to Note</h3>
From the fiscal third quarter of 2024, Cardinal Health started reporting its results under new operating segments &mdash; Pharmaceutical and Specialty solutions, Global Medical Products and Distribution (GMPD) segment, nuclear at-Home and OptiFreight.
The third quarter of fiscal 2024 witnessed an uptick in revenues in the Pharmaceutical segment, which amounted to approximately $50.7 billion, up 9% on a year-over-year basis. The Pharmaceutical Distribution and Specialty Solutions segment&#39;s performance highlighted branded pharmaceutical sales growth from existing customers. The segment&#39;s profit increased 4% during the fiscal third quarter. This momentum is likely to have continued in the&nbsp;fiscal fourth quarter&nbsp;as well. Moreover, the rising demand for GLP-1 medications is likely to have acted as a tailwind.
Higher contributions from brand and specialty products, as well as the effectiveness of the generics program, drove the positive outcome of the pharmaceutical segment in the last reported quarter. This trend is likely to have continued in the to-be-reported quarter as well.
Medical segment&#39;s revenues grew 4% year over year in the last reported quarter, driven by growth in at-Home Solutions and GMPD. The segment&#39;s profit was $20 million in the fiscal third quarter. This upside was driven by an improvement in net inflationary impacts, including mitigation initiatives, which are likely to have boosted the medical segment&#39;s results in the fiscal fourth quarter as well.
In March 2024, Cardinal Health completed the acquisition of Specialty Networks, which is likely to expand the company&#39;s offerings with physicians in the areas of urology, GI, and rheumatology. Specialty Networks is providing a proven platform in PPS analytics that the company is likely to further invest in fiscal 2025 and look to extend to other therapeutic areas such as oncology.
Per the third-quarter earnings call, CAH&#39;s integration of Specialty Networks is underway, and the reaction from the providers the company serves has been extremely encouraging. The platform&#39;s insight generation capabilities for clinicians are robust, which is likely to accelerate CAH&#39;s upstream data and research opportunities with biopharma manufacturers. The company is expected to provide further updates in this regard in the to-be-reported quarter.
The company announced its new distribution center being built in South Carolina, which, per management, features the fastest order fulfillment system per square foot in the market. The center is scheduled to open by early next fiscal year. New distribution centers are likely to aid the company&#39;s supply chain, thus improving revenues. Cardinal Health is likely to provide further updates in this regard in the to-be-reported quarter.
<h3>What the Zacks Model Unveils</h3>
Our proven model does not conclusively predict an earnings beat for Cardinal Health this time around. The combination of a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP:&nbsp;Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -0.17%.
Zacks Rank:&nbsp;Cardinal Health currently carries a Zacks Rank #3.
<div class="chart_embed">
<h3>Cardinal Health, Inc. Price and EPS Surprise</h3>
<img alt="Cardinal Health, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/50/1723470107.png" style="height:263px; width:544px" title="" />
Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote
</div>
<h3>Stocks to Consider</h3>
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Phibro Animal Health&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) has an Earnings ESP of +0.99% and a Zacks Rank of 2 at present.
The stock has risen 59.5% year to date. PAHC&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 2.30%.
Owens &amp; Minor&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>) has an Earnings ESP of +1.54% and a Zacks Rank of 2 at present.
The stock has lost 14.6% year to date. OMI&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 11.99%.
ResMed&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) has an Earnings ESP of +2.85% and a Zacks Rank of 3 at present.
The stock has risen 16% year to date. RMD&#39;s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.81%.
<a href="https://www.zacks.com/stock/news/2320761/what-s-in-store-for-cardinal-health-cah-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2320761">To read this article on Zacks.com click here.</a>

PAHC

What's in Store for Cardinal Health in Q4 Earnings?

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $23 to $18.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $18

After spiking in the first quarter of 2024, inflation has been weakening from April. In fact, per the June data, the annual rate of inflation dropped to its lowest level in more than two years, raising hopes of a rate cut in September. This bodes well as low interest rates improve consumer outlays, decrease the cost of borrowings and, in turn, boost economic growth.
Additionally, second-quarter quarter earnings have been impressive so far, with many companies reporting better-than-expected earnings per share. Given this brightening scenario, investors would like to design a winning portfolio of stocks for impressive returns. One way to do so is by following broker advice. Stocks like ADTRAN (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtn#NASDAQ">ADTN</a>), Bread Financial (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfh#NYSE">BFH</a>), Owens &amp; Minor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/omi#NYSE">OMI</a>), Bally&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baly#NYSE">BALY</a>) and AMC Networks (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amcx#NASDAQ">AMCX</a>) are worth monitoring.
We have designed a screen to shortlist stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks. Also, since the price/sales ratio is a strong complementary valuation metric in the presence of broker information, it has been included. The price/sales ratio takes care of the company&#39;s top line, making the strategy a well-rounded one.
<h3>Screening Criteria</h3>
# (Up- Down Rating)/ Total (4 weeks) =Top #75&nbsp;(This gives the list of the top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10&nbsp;(This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10&nbsp;(The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks with respect to this ratio).
Price greater than 5&nbsp;(as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days&nbsp;(Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000&nbsp;(This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com&nbsp;(This takes out the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
ADTRAN is poised to capitalize on its strengths in ultra-broadband and fiber-to-the-home solutions along with Software-Defined or SD access and Ethernet passive optical network solutions. Its global leadership in SD access is likely to ensure a steady stream of revenues as it helps clients reduce costs and accelerate service delivery and deployment.
ADTN currently carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for ADTN&#39;s 2024 earnings has remained stable over the past 60 days.
Bread Financial is based in Columbus, OH. The company continues to benefit from data-driven marketing strategies. Solid receivables growth in Card Services should drive its top line. Acquisitions and divestitures will aid the company in growing inorganically and expanding its international footprint.
Over the past 60 days, the Zacks Consensus Estimate for BFH&#39;s current-quarter earnings has increased 31%. Bread Financial currently carries a Zacks Rank #3.
Owens &amp; Minor is a global healthcare solutions company. Shares of this Zacks Rank #3 company have gained 28% in the past month. In 2024, the company&#39;s earnings are expected to witness growth of 14.7% from 2023 actuals.
The Zacks Consensus Estimate for Owens &amp; Minor&#39;s 2024 earnings is currently pegged at $1.56 per share, indicating a 2% upward revision over the past 30 days. OMI&#39;s earnings surpassed estimates in each of the last four quarters, with an average beat of 11.1%.
Bally&#39;s shares have been moving north lately following news of its merger agreement with Standard General L.P., valued at approximately $4.6 billion. The agreement involves combining Bally&#39;s with The Queen Casino &amp; Entertainment Inc., a regional casino operator.&nbsp;
Over the past 60 days, the Zacks Consensus Estimate for BALY&#39;s current-quarter earnings has increased 57%. The company currently carries a Zacks Rank #2 (Buy).
AMC Networks is benefiting from a rising focus on high-quality programming and strong partnerships, which, in turn, are driving subscriber growth and ad revenues.
Over the past 60 days, the Zacks Consensus Estimate for AMCX&#39;s current-quarter earnings has remained stable at $1.38 per share. The radio and television broadcast company currently carries a Zacks Rank #3.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
<a href="https://www.zacks.com/stock/news/2315768/5-stocks-loved-by-brokers-worth-watching-currently?cid=CS-BENZ-FT-analyst_blog|rw-2315768">To read this article on Zacks.com click here.</a>

Mid Cap

ADTN

AMCX

BALY

5 Stocks Loved by Brokers Worth Watching Currently

Owens & Minor shares are trading lower. The company reported Q2 financial results.

Barclays analyst Stephanie Davis maintained a Hold rating on Owens & Minor (OMI – Research Report) today and set a price target of $14.00. The comp...

Barclays Sticks to Their Hold Rating for Owens & Minor (OMI)

Barclays analyst Stephanie Davis lowered the firm's price target on Owens & Minor to $14 from $18 and keeps an Equal Weight rating on the shares. T...

Owens & Minor price target lowered to $14 from $18 at Barclays

Citi lowered the firm's price target on Owens & Minor to $18.50 from $21 and keeps a Buy rating on the shares. The company's Q3 results "were a bit...

Owens & Minor price target lowered to $18.50 from $21 at Citi

Baird analyst Eric Coldwell lowered the firm's price target on Owens & Minor to $14 from $19 and keeps a Neutral rating on the shares. The firm sai...

Owens & Minor price target lowered to $14 from $19 at Baird

Owens & Minor: Very Undervalued Healthcare Business With Long-Term Agreements

Owens & Minor (OMI) has disclosed a new risk, in the Corporate Activity and Growth category. Owens & Minor faces significant risks associated with ...

Owens & Minor's Rotech Acquisition: Navigating Integration Challenges and Risks

Wall Street favors small caps for their high growth potential, broad sector exposure, and strong performance during economic recoveries, especially as rate cuts lower borrowing costs. Hence, it may be wise to consider buying high-potential small-cap stocks: Owens & Minor (OMI), Orion (OEC), and Cerus (CERS). Read on... Small-cap stocks benefit greatly from lower interest rates, as they typically carry higher debt levels than large-cap companies. Moreover, small-cap stocks offer diverse industry exposure beyond tech, including in medical, biotech, and chemical industries, providing growth potential across multiple sectors.
Therefore, for investors seeking high-upside opportunities, fundamentally strong small-cap stocks like Owens &amp; Minor, Inc. (<a href="https://stocknews.com/stock/OMI/">OMI</a>), Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>), and Cerus Corporation (<a href="https://stocknews.com/stock/CERS/">CERS</a>) are worth considering.
Historically, small-cap stocks have outperformed large caps during economic recoveries. As inflation stabilizes and if the economy strengthens, small-cap stocks could benefit significantly. Small-cap stocks offer broad sector exposure, which helps reduce regulatory and sector-specific risks while providing diverse investment opportunities.
With inflation currently at <a href="https://www.reuters.com/markets/rates-bonds/traders-stick-bets-25-bps-fed-rate-cuts-nov-dec-2024-10-31/">2.1%</a>, just above the Fed's target, rate cuts are anticipated in December. These cuts could reduce borrowing costs, stimulate consumer spending, and boost small-cap stock valuations. Alongside, the U.S. economy expanded by an annualized <a href="https://www.conference-board.org/brief/global-economy/gdp-q3-2024">2.8% in the third quarter</a>, highlighting further optimism for the small caps.
Furthermore, small-cap stocks often yield higher returns in volatile markets due to increased investor demand for growth-oriented opportunities. Considering these conducive trends, let's examine the fundamentals of the above-mentioned small-cap stocks.
Owens &amp; Minor, Inc. (<a href="https://stocknews.com/stock/OMI/">OMI</a>)
Valued at $1.03 billion by market cap, OMI, along with its subsidiaries, operates as a healthcare solutions company worldwide. It functions through two segments: Products &amp; Healthcare Services and Patient Direct.
On September 10, 2024, OMI announced a partnership with Google Cloud to enhance its QSight clinical inventory management system. This collaboration aims to improve inventory optimization for hospitals, leveraging Google Cloud's AI capabilities for real-time insights and predictive management.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, OMI's 3.12% is 22.5% higher than the 2.55% industry average. Its 4.29% trailing-12-month levered FCF margin is 150.4% higher than the 1.71% industry average. Likewise, the stock's 1.99x trailing-12-month asset turnover ratio is 384.8% higher than the 0.41x industry average.
OMI's revenue for the fiscal second quarter ended June 30, 2024, increased 4.2% year-over-year to $2.67 billion. Its non-GAAP operating income was $76.26 million, up 23% year-over-year. Additionally, the company's non-GAAP net income and non-GAAP net income per common share were $28.15 million and $0.36, respectively, up 98% and 100% over the prior-year quarter.
For the quarter ended September 30, 2024, OMI's revenue is expected to grow 3.4% year-over-year to $2.68 billion. Its EPS for the quarter ending March 31, 2025, is expected to rise 38.4% year-over-year to $0.26. It surpassed the Street EPS estimates in each of the trailing four quarters.
Over the past month, OMI's stock has declined 8.2% to close the last trading session at $13.36. The average analyst price target of $20 indicates a <a href="https://www.tipranks.com/stocks/omi/forecast">49.7% upside potential</a>.
OMI's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect an optimistic outlook. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Growth and Value. It is ranked #53 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. To see OMI's Momentum, Stability, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/OMI/">click here</a>.
Orion S.A. (<a href="https://stocknews.com/stock/OEC/">OEC</a>)
Valued at $898.69 million by market cap, Headquartered in Senningerberg, Luxembourg, OEC engages in the manufacture and sale of carbon black products. It operates through two segments: Specialty Carbon Black and Rubber Carbon Black.
In terms of the trailing-12-month Capex / Sales, OEC's 10% is 28.9% higher than the 7.76% industry average. Its 16.18% trailing-12-month Return on Common Equity is 185.8% higher than the 5.66% industry average. Also, the stock's 7.43% trailing-12-month Return on Total Capital is 52.3% higher than the 4.88% industry average.
During the fiscal second quarter ended June 30, 2024, OEC's net sales rose 4% year-over-year to $477 million. Its operating income was $109.80 million. Similarly, the company's adjusted net income and adjusted EPS were $24.50 million and $0.41, respectively.
Street expects OEC's revenue for the quarter ended September 30, 2024, to increase 3.1% year-over-year to $480.67 million. Its EPS for the quarter ending December 31, 2024, is expected to rise 143.9% year-over-year to $0.41. OEC's stock has declined 11.2% over the past year to close the last trading session at $15.40. The average analyst price target of $22 indicates a <a href="https://www.tipranks.com/stocks/semr/forecast">42.1% upside potential</a>.
OEC's strong fundamentals are reflected in its POWR Ratings. It has a B grade for Value. It is ranked #38 out of 80 stocks in the B-rated <a href="https://stocknews.com/category/chemicals/">Chemicals</a> industry. Beyond what we stated above, we also have given OEC grades for Growth, Momentum, Stability, Sentiment, and Quality. Get all the OEC ratings <a href="https://stocknews.com/stock/OEC/">here</a>.
Cerus Corporation (<a href="https://stocknews.com/stock/CERS/">CERS</a>)
Valued at $282.29 million by market cap, CERS operates as a biomedical products company, focusing on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
In terms of the trailing-12-month asset turnover ratio, CERS' 0.89x is 117.3% higher than the 0.41x industry average.
CERS's total revenue for the fiscal third quarter ended September 30, 2024, increased 7.2% year-over-year to $50.66 million. Its adjusted EBITDA was $4.39 million, compared to an adjusted EBITDA loss of $972 thousand in the prior-year quarter. Additionally, the company's gross profit on product revenue was $26.20 million, up 20.1% from the year-ago value.
Analysts expect CERS' revenue for the quarter ending December 31, 2024, to increase 8.4% year-over-year to $50.69 million. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, CERS' stock has gained 14.5% to close the last trading session at $1.58. The average analyst price target of $4 indicates a <a href="https://www.tipranks.com/stocks/semr/forecast">151.6% upside potential</a>.
CERS' POWR Ratings reflect its solid prospects. CERS has a B grade for Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #121 out of 328 stocks. To access CERS' additional ratings for Growth, Value, Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/CERS/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
OMI shares rose $1.00 (+8.33%) in after-hours trading Monday. Year-to-date, OMI has declined -37.73%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/omi-oec-cers-3-high-potential-small-cap-stocks-wall-street-loves/>3 High-Potential Small-Cap Stocks Wall Street Loves</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Potential Small-Cap Stocks Wall Street Loves

The FDA posted to its set a warning letter previously sent to Owens & Minor, Inc. dba American Contract Systems, following an inspection that was c...

Comments

Owens & Minor

Notizie

Ultime notizie per Owens & Minor (NYSE:OMI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO